Tscan Therapeutics Inc (TCRX)
Healthcare
Biotechnology
0.74 $
-1.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Tscan Therapeutics Inc (TCRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 90.7% of the shares are freely tradable; institutional investors hold 59.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
59.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
90.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
1.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
61Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Lynx1 Capital Management, LP | 12.27 | 8,019,148 | +0.0 | 03/31/2026 |
| Bvf Inc | 8.51 | 5,564,290 | +6.5 | 03/31/2026 |
| Baker Bros Advisors LP | 4.26 | 2,784,792 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 3.79 | 2,475,733 | +6.8 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.30 | 2,154,256 | +0.0 | 03/31/2026 |
| BlackRock Inc | 2.82 | 1,840,952 | -0.4 | 03/31/2026 |
| Millennium Management LLC | 2.23 | 1,460,285 | +261.8 | 03/31/2026 |
| Renaissance Technologies Corp | 2.09 | 1,364,783 | +19.6 | 03/31/2026 |
| Deer Management Co. LLC | 1.91 | 1,245,504 | +0.0 | 12/31/2025 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.30 | 1,500,337 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.